NeuroOne Medical Technologies Corp. Announces 2024 Annual Meeting of Stockholders
Ticker: NMTC · Form: DEF 14A · Filed: Jan 29, 2024 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | DEF 14A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $100, $3, $171,169, $1,952,441, $5.2 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: NeuroOne Medical, Annual Meeting, Proxy Statement, Medical Devices, OneRF Ablation System
TL;DR
<b>NeuroOne Medical Technologies Corp. is holding its 2024 annual meeting on March 14, 2024, highlighting advancements in its neurological product portfolio, including the new OneRF Ablation System.</b>
AI Summary
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed a Proxy Statement (DEF 14A) with the SEC on January 29, 2024. NeuroOne Medical Technologies Corp. will hold its 2024 annual meeting of stockholders on March 14, 2024, at 9:00 a.m. local time in Eden Prairie, MN. The company's fiscal year 2023 was marked by advancements in its platform technology, including cortical strip, grid, and sEEG electrodes. NeuroOne expanded its product portfolio to include the OneRF Ablation System, a combination diagnostic and therapeutic product. Significant progress was made in fiscal 2023 on product development programs for drug delivery and spinal cord stimulation. The company is focused on capitalizing on near-term and longer-term opportunities in fiscal year 2024.
Why It Matters
For investors and stakeholders tracking NEUROONE MEDICAL TECHNOLOGIES Corp, this filing contains several important signals. The annual meeting provides a platform for NeuroOne to update shareholders on its strategic progress and future outlook, particularly concerning its expanded product offerings. The introduction of the OneRF Ablation System signifies a move into combination diagnostic and therapeutic products, potentially creating a paradigm shift in neurological surgery and impacting future revenue streams.
Risk Assessment
Risk Level: low — NEUROONE MEDICAL TECHNOLOGIES Corp shows low risk based on this filing. The filing is a routine DEF 14A proxy statement, which typically contains standard disclosures about annual meetings and executive compensation, posing no immediate material risk.
Analyst Insight
Review the proposals and director elections at the upcoming annual meeting to understand potential governance changes and management's strategic direction.
Key Numbers
- 2024 — Annual Meeting Year (2024 annual meeting of stockholders)
- March 14 — Annual Meeting Date (March 14, 2024)
- 9:00 a.m. — Annual Meeting Time (9:00 a.m. local time)
- 2023 — Fiscal Year (Fiscal 2023 was a transformational year)
Key Players & Entities
- NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Registrant
- Original Source Entertainment, Inc. (company) — Former company name
- March 14, 2024 (date) — Date of annual meeting
- 9:00 a.m. (time) — Time of annual meeting
- Eden Prairie, MN (location) — Location of annual meeting
- Evo ® Cortical Electrode (product) — Diagnostic product
- Evo ® sEEG Depth Electrode (product) — Diagnostic product
- OneRF ® Ablation System (product) — Combination diagnostic and therapeutic product
FAQ
When did NEUROONE MEDICAL TECHNOLOGIES Corp file this DEF 14A?
NEUROONE MEDICAL TECHNOLOGIES Corp filed this Proxy Statement (DEF 14A) with the SEC on January 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC).
Where can I read the original DEF 14A filing from NEUROONE MEDICAL TECHNOLOGIES Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NEUROONE MEDICAL TECHNOLOGIES Corp.
What are the key takeaways from NEUROONE MEDICAL TECHNOLOGIES Corp's DEF 14A?
NEUROONE MEDICAL TECHNOLOGIES Corp filed this DEF 14A on January 29, 2024. Key takeaways: NeuroOne Medical Technologies Corp. will hold its 2024 annual meeting of stockholders on March 14, 2024, at 9:00 a.m. local time in Eden Prairie, MN.. The company's fiscal year 2023 was marked by advancements in its platform technology, including cortical strip, grid, and sEEG electrodes.. NeuroOne expanded its product portfolio to include the OneRF Ablation System, a combination diagnostic and therapeutic product..
Is NEUROONE MEDICAL TECHNOLOGIES Corp a risky investment based on this filing?
Based on this DEF 14A, NEUROONE MEDICAL TECHNOLOGIES Corp presents a relatively low-risk profile. The filing is a routine DEF 14A proxy statement, which typically contains standard disclosures about annual meetings and executive compensation, posing no immediate material risk.
What should investors do after reading NEUROONE MEDICAL TECHNOLOGIES Corp's DEF 14A?
Review the proposals and director elections at the upcoming annual meeting to understand potential governance changes and management's strategic direction. The overall sentiment from this filing is neutral.
How does NEUROONE MEDICAL TECHNOLOGIES Corp compare to its industry peers?
NeuroOne Medical Technologies operates in the medical device industry, specifically focusing on neurological applications and surgical instruments.
Are there regulatory concerns for NEUROONE MEDICAL TECHNOLOGIES Corp?
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
Industry Context
NeuroOne Medical Technologies operates in the medical device industry, specifically focusing on neurological applications and surgical instruments.
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
What Investors Should Do
- Review the agenda for the 2024 Annual Meeting of Stockholders.
- Examine the proposals to be voted on by shareholders.
- Assess the company's progress and strategic direction as outlined in the proxy statement.
Key Dates
- 2024-03-14: Annual Meeting of Stockholders — Key date for shareholder engagement and voting on corporate matters.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a proxy statement typically filed annually to provide information to shareholders regarding the annual meeting. It does not represent a change from previous filings in terms of its nature but provides updated information for the current year.
Filing Stats: 4,133 words · 17 min read · ~14 pages · Grade level 14.6 · Accepted 2024-01-29 09:00:30
Key Financial Figures
- $100 — rodes is currently estimated to be over $100 million USD. •  &
- $3 — ation market which is estimated to be a $3 billion market opportunity world
- $171,169 — ctrodes, Product Revenue increased from $171,169 in fiscal year 2022 to $1,952,441 in fi
- $1,952,441 — ed from $171,169 in fiscal year 2022 to $1,952,441 in fiscal year 2023. In July 202
- $5.2 — g of common stock, with net proceeds of $5.2 million. In addition, the Compan
- $1.77 — the ATM program at an average price of $1.77 per share, from which we received net p
- $2.5 — from which we received net proceeds of $2.5 million during fiscal year 2023.
- $1.46 — the ATM program at an average price of $1.46 per share and received net proceeds of
- $2.8 — per share and received net proceeds of $2.8 million. With the pending commer
- $0.001 — any’s common stock, par value of $0.001 per share (the “Common Stock
Filing Documents
- def14a0124_neuroone.htm (DEF 14A) — 938KB
- tbarchart_001.jpg (GRAPHIC) — 279KB
- tbarchart_002.jpg (GRAPHIC) — 272KB
- timage_001.jpg (GRAPHIC) — 76KB
- timage_002.jpg (GRAPHIC) — 131KB
- timage_003.jpg (GRAPHIC) — 454KB
- timage_004.jpg (GRAPHIC) — 222KB
- tneuro_logo.jpg (GRAPHIC) — 40KB
- tproxy_001.jpg (GRAPHIC) — 1184KB
- tproxy_002.jpg (GRAPHIC) — 1073KB
- tsignature_neuro.jpg (GRAPHIC) — 14KB
- 0001213900-24-007191.txt ( ) — 6099KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   16 EXECUTIVE OFFICERS   18
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   20 PAY VERSUS PERFORMANCE   26 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS   29 ADDITIONAL INFORMATION   30 OTHER MATTERS   33 i Table of Contents NEUROONE MEDICAL TECHNOLOGIES CORPORATION PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS GENERAL INFORMATION ABOUT THE ANNUAL MEETING Our Board of Directors (the “Board”) solicits your proxy on our behalf for the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) and at any postponement or adjournment of the Annual Meeting for the purposes set forth in this proxy statement (the “Proxy Statement”) and the accompanying Notice of 2024 Annual Meeting of Stockholders (the “Notice”). The Annual Meeting will be held at our principal executive offices at 7599 Anagram Dr., Eden Prairie, MN 55344, on Thursday, March 14, 2024 at 9:00 a.m. local time. This Proxy Statement is first being sent to stockholders on or about January 29, 2024. We currently intend to hold the Annual Meeting in person. However, in the event we determine it is not possible or advisable to hold the Annual Meeting in person, we will publicly announce alternative arrangements for the Annual Meeting as promptly as practicable before the Annual Meeting. Please monitor our website at www.n1mtc.com for updated information. Unless we state otherwise or the context otherwise requires, references in this Proxy Statement to “we,” “our,” “us,” or the “Company” are to NeuroOne Medical Technologies Corporation, a Delaware corporation. Purpose of the Annual Meeting At the Annual Meeting, stockholders will act upon the proposals described in this Proxy Statement. In addition, we will consider any other matters that are properly presented for a vote at the Annual Meeting. We are not aware of any other matters to